Evidence map›Paper›PMID 30806067›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer

Seyed Mohsen Miresmaeili, Fatemeh Jafari

Open access · goldAbstract readCase Reports
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Seyed Mohsen MiresmaeiliDepartment of Biology, Science and Arts University, Yazd, Iran. Email: miresmaeili@sau.ac.ir
Fatemeh Jafari
Yazd University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer is the most common cancer diagnosed among women, Tumor suppressor genes such as BRCA1 involved in cell cycle control and repairing of DNA damage. BRCA1 is a risk factor gene that alteration in its protein cause in susceptibility to breast or ovarian cancer. Short tandem repeat (STR) polymorphism is linked to some disease. Objective: The aim of this study was screening a new mutation in patients with familial breast cancer. Materials and Methods: In this study, 200 women with breast cancer were participated. Among the patients, 40 women suffer from familial breast cancer. After DNA extraction from peripheral blood samples, Exons 16 to 23 of BRCA1 gene directly analyzed in SSCP gel electrophoresis followed by direct sequencing. Results: After direct sequencing, a new mutation was detected in intron 17 of BRCA1 gene. Three patients of one family have a germ line intronic mutation in the BRCA1 gene (IVS17-27delA). Also, this mutation in this family is linked to a haplotype of intragenic short tandem repeat (STR) in the BRCA1 gene. Conclusion: By Screening of gene mutations can be found association of mutation and incidence of disease. Also, studying the mutation in families and finding specific hereditary patterns in that family can be effective in prognosis of disease in other family members.

Indexed as

Biomarkers, TumorBRCA1 ProteinBreast NeoplasmsGenetic Predisposition to DiseaseGerm-Line MutationHaplotypesIntronsAdultFemaleFollow-Up StudiesHumansMiddle AgedPedigreePrognosisBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA1 geneBreast cancerhaplotypeintronic mutation

Identifiers

PMID30806067
PMCPMC6897036
OpenAlexW2909110462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.